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inTRODUCTiOn
Only two new drugs have been licensed for the treatment of epithelial ovarian cancer in the last 
5 years (bevacizumab and olaparib). These are also the only two molecularly targeted agents licensed 
in this disease. As we continue to move into the genomic era of cancer therapy, it is clear that optimal 
therapy is going to depend on molecular stratification and that the stratification itself is going to need 
to contend with tumor heterogeneity. In this article, we discuss molecular stratification and tumor 
heterogeneity in the context of high-grade serous ovarian cancer.
The development of bevacizumab and olaparib has provided contrasting examples of stratification 
in molecularly targeted agents. Bevacizumab is licensed as an unselected agent, currently without 
molecular (or indeed histological) stratification. However, emerging data may be able to help us 
refine which patients may benefit the most from this agent (and which may not require it). Any such 
refinement can be expected to increase the median benefit in the selected population and reinforce 
the cost:benefit advantage. Conversely, olaparib is licensed as a highly selected agent, currently by 
genomic or somatic BRCA1/BRCA2 mutation in high-grade serous cancer. However, emerging data 
may be able to help us expand its role into tumors with other homologous recombination deficits 
(while also determining if all BRCA1/BRCA2 mutations respond equally). For both agents, however, 
cancers progress even on continuous therapy and targeting the resistant clones that have emerged 
from tumor heterogeneity will be key to extending benefit for these patients.
BEVACiZUMAB
Bevacizumab is the first vascular endothelial growth factor (VEGF)-targeted therapy to have been 
licensed in ovarian cancer; by the European Medicines Agency (EMA) in 2011 and the United States 
Food and Drug Administration (FDA) in 2014. These licenses differ although in both cases the 
bevacizumab is given in combination with chemotherapy. The EMA license was the result of first 
line data from the GOG 218 (1) and ICON7 (2) studies, second line platinum sensitive data from 
OCEANS (3) and second line platinum resistant data from AURELIA (4) all of which demonstrated 
a statistically significant increase in progression free survival compared to chemotherapy alone. The 
FDA license relates to the platinum resistant setting only and was dependent on the data from the 
AURELIA study. The optimal setting for this treatment is unknown (5), as is the value of treating 
through progression or utilizing combinations of anti-angiogenic therapies. VEGF-targeted therapy 
is clearly an active approach in ovarian cancer (at least in combination with chemotherapy) and other 
anti-angiogenic agents have been investigated in this setting including pazopanib (6), cedirinib (7), 
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nintedanib (8), aflibercept (9), trebananib (10), sunitinib (11), 
sorafenib (12), and (PDGFR) imatinib (13).
Given the mode of action, it was not unreasonable to seek 
potential broad activity for bevacizumab and, as with all previ-
ous agents in ovarian cancer, these trials had no molecularly or 
histological stratification. However, potential biomarkers are 
now emerging for benefit from bevacizumab (14), building on 
the extensive translational work incorporated in ICON7. For 
blood biomarkers, a link is evident between circulating Ang1 
plus Tie2 levels and progression free survival (15), with most 
of the benefit from bevacizumab in the high Ang1-low Tie2 
group (HR 0.27), no significant effect in the low Ang1 group 
and a detriment in the high Ang1-high Tie2 group (HR 3.6). A 
possible link noted with plasma VEGF-A in other tumor types 
(16), was not seen in this ovarian dataset. For tissue biomark-
ers, a signature made up of tissue mesothelin, FLT4 and AGP 
and blood CA125 also has potential to strongly differentiate 
between benefit and harm from bevacizumab but was limited by 
patient numbers in the analysis (17). Recently, a transcriptomic 
signature has been presented (18), which identifies distinct 
molecular subgroups of high-grade serous ovarian cancer that 
respond very differently to bevacizumab. In this analysis, the 
two proangiogenic subgroups had a poorer overall survival but 
appeared to contain all the benefit from bevacizumab. The other, 
immune subgroup had a superior prognosis but had a detriment 
(HR 2.0) from bevacizumab. This data will need confirmation 
in further datasets but the above examples suggest that we are 
getting closer to a molecular biomarker for bevacizumab benefit 
(and resistance). The next step will of course be identifying if 
these molecular signals also emerge in acquired resistance and 
if they indicate a druggable pathway to improve or extend the 
activity of VEGF-directed therapies to resistant tumors (or resist-
ant clonal subpopulations). The story may be complicated by the 
fixed duration of bevacizumab in some studies (such as ICON7) 
but continuous maintenance therapy is the expected direction of 
travel for the future.
Hopefully, the above approaches can help address the 
mystery of why VEGF-directed therapy does not yet seem to 
be living up to its clear potential. In the phase 2 single agent 
studies (19, 20), bevacizumab had a roughly 20% objective 
response rate (ORR), a figure matched by the additional ORR 
benefit seen compared to chemotherapy alone in phase 2 and 
phase 3 combination studies, regardless of setting (Table 1). It 
is unclear why this clear ORR benefit has not translated into 
more impressive PFS or OS benefits in the phase 3 first line 
studies (PFS benefit 3.8m in GOG 218 and 2 months in ICON7, 
with updated analysis of the latter non-significant and no OS 
benefit in the ITT population). It seems likely that there is a 
subset benefiting greatly from therapy (and this subset will be 
evident when response rate is the primary endpoint, as in some 
phase 2 studies) but that the effect is being diluted by the current 
lack of a selection biomarker and is therefore harder to detect 
when PFS is the primary endpoint (as in the phase 3 studies). 
Identifying this subset may be the key to widening its licensed 
indications. Identifying the tumor heterogeneity that leads to 
resistance to VEGF-directed therapy may be the key to improv-
ing and prolonging the benefit.
OLApARiB
Olaparib is the first poly ADP ribose polymerase (PARP)-
inhibitor to have been licensed in ovarian cancer (2014). The 
EMA license is as post-chemotherapy maintenance in patients 
with germline or somatic BRCA1 or BRCA2 mutations. This 
was as a result of the subgroup analysis (21) of BRCA1/2 mutant 
cancers (germline or somatic), in the molecularly unselected 
TABLE 1 | pivotal phase 2 and phase 3 bevacizumab studies in ovarian cancer.
Study patients % platinum resistant Response rate (%) Median pFS (months) Median OS (months)
SinGLE AGEnT pHASE 2 BEVACiZUMAB STUDiES
GOG-170D
Burger et al. (19)
62 58 21 4.7 17
AVF2949
Cannistra et al. (20)a
44 100 16 4.4 10.7
Study Agents Setting Response rate Median pFS (months) Median OS (months)
Bev no bev Bev no bev Bev no bev
RAnDOMiZED pHASE 3 BEVACiZUMAB STUDiES
GOG218 Carbo/pac + bev or plac  
(concom and maint)
First line Unknown 14.1 10.3 39.7 39.3
Burger et al. (1) P < 0.001 N.S.
ICON7 Carbo/pac ± bev maint First line 67% 48% 19.8 17.4 44.5 44.6
Perren et al. (2) P < 0.001 P = 0.04 N.S.
OCEANS Carbo/gem + bev or plac 
(concom and maint)
Platinum  
sensitive relapse
78% 57% 12.4 8.4 33.3 35.2
Aghajanian et al. (3) P < 0.0001 P < 0.0001 N.S.
AURELIA Chemo vs. chemo  
plus bev
Platinum  
resistant relapse
31% 13% 6.7 3.4 16.6 13.3
Pujade-Lauraine et al. (4) P < 0.001 P < 0.001 N.S.
aStudy stopped prematurely because five gastrointestinal perforations out of 44 patients.
PFS, progression free survival; OS, overall survival; JCO, Journal of Clinical Oncology; bev, bevacizumab; NEJM, New England Journal of Medicine; carbo, carboplatin; pac, 
paclitaxel; plac, placebo; concom, concomitant; maint, maintenance; gem, gemcitabine; chemo, chemotherapy.
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Study 19 of relapsed platinum sensitive high-grade serous ovar-
ian cancer (22). The FDA license is as monotherapy in patients 
with deleterious or suspected deleterious germline BRCA 
mutated advanced ovarian cancer who have been treated with 
three or more prior lines of chemotherapy. PARP inhibitors have 
demonstrated strong activity in molecularly selected populations 
and other agents include rucaparib (23), niraparib (24), veliparib 
(25), and talazoparib (26).
The target population was a clear priority from the original 
phase 1 study, where BRCA1/BRCA2 mutation carriers were 
the predominant responders, leading to a BRCA1/BRCA2 
expansion (27), with promising activity in ovarian cancer (28), 
which was subsequently confirmed in phase 2 (29). However, 
BRCA1/BRCA2 mutation is known not to be an absolute bio-
marker for sensitivity and other homologous recombination 
defects have been strongly implicated as additional predictive 
biomarkers (30). Study 19 represented a pragmatic approach to 
enrich for this whole group without genetic testing by looking 
at a platinum-sensitive, high-grade serous histopathology, ovar-
ian population (22), given the known link between platinum 
sensitivity, high-grade serous histopathology and BRCA1/2 or 
wider homologous recombination gene defects (31, 32), even in 
non-hereditary cases (33, 34). However, although this study did 
identify activity in the non-BRCA mutant subgroup (HR 0.54), 
the dramatic effect was really in the BRCA1/2 mutant subgroup 
(HR 0.18), and the diluted overall signal risked being a barrier 
to licensing of these important, active agents. Therefore, olaparib 
is now licensed for BRCA1/2 mutant cancers and steps are being 
taken to identify additional predictive biomarkers, including 
other known homologous recombination defects. However, 
predictive biomarkers are seldom binary and olaparib provides a 
good example where molecular heterogeneity between patients 
and within tumors leads to significant variation in activity and 
resistance.
When comparing different patients with different homologous 
recombination deficient tumors, we are beginning to realize that 
all BRCA molecular deficits are not equal – epigenetic changes are 
clearly a different biology to genetic (30, 32, 35) but what about 
different specific mutations or the difference between germline 
and somatic? Today, it is generally accepted that the different 
histological subgroups of epithelial ovarian cancer represent dif-
ferent diseases (36). However, as with other cancers, it is also clear 
that different molecular subgroups (30) of high-grade serous 
ovarian cancer can have different phenotypes (37) and outcomes 
(38, 39), with homologous recombination defects a clear example. 
It is natural to extend this to specific homologous recombina-
tion proteins and, even further, to specific mutations/defects of 
individual proteins.
Molecular heterogeneity within an individual’s cancer may be 
just as important. While adaptive epigenetic changes have been 
implicated in platinum resistance (40), a more striking mecha-
nism of resistance may underlie some of the cross-resistance of 
platinum therapy and PARP inhibition that has lead to the focus 
on platinum sensitive disease in the clinic (28, 41). This is the 
phenomenon where inactivating mutations within the BRCA1/
BRCA2 genes revert to functional genes (41–45), clearly demon-
strating the strong selection pressures, which drive outgrowth of 
a resistant subclone that lacks the one main feature that defined, 
or even induced, the original cancer but which subsequently had 
become its Achilles heel. In effect, the tumor is doing whatever 
it can to evade the agents used against it, even if that means re-
expressing the gene that it had to lose in order to become a cancer 
cell in the first place.
Of course, not every individual’s tumor will contain the resist-
ant subclones that drive this response and much can be learned 
from the super-responders (28, 46) who give an example of what 
we might hope to achieve if we could overcome that heterogeneity.
THE FUTURE
Clearly, future optimal therapy for high-grade serous ovarian 
cancer will depend on optimal molecular stratification and this is 
just as true for bevacizumab and olaparib as it will be for future 
agents. While this will help rise to the challenge of optimizing 
therapy for inter-patient molecular heterogeneity, monotherapy 
may never overcome intra-patient heterogeneity. If we want to 
improve the durability of responses, that pool of resistant clones 
may need to be narrowed by using combination therapies. Indeed, 
recent clinical data for the addition of the VEGFR inhibitor, cedi-
rinib, to olaparib have shown a significant increase in response 
rate and a near-doubling of progression free survival (47). The 
majority of this benefit was in the BRCA1/BRCA2 wild-type (or 
unknown) group, perhaps demonstrating that combinations can 
overcome monotherapy dependencies but also highlighting that 
there is still a lot to learn about biomarkers for anti-angiogenic 
and PARP inhibitor agents in ovarian cancer.
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